Zevalin® Receives Positive CHMP Opinion in Europe for First-Line Consolidation Treatment
- Details
- Category: Bayer
Bayer Schering Pharma AG has received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) recommending Zevalin® ([90Y]-ibritumomab tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma (FL) in Europe.
Genzyme Withdraws Bioenvision's European Filing of Evoltra® in Elderly AML Patients
- Details
- Category: Genzyme
Genzyme Corp. (Nasdaq: GENZ) announced the withdrawal of the European application to extend the Evoltra® (clofarabine) product label to include the treatment of elderly patients with acute myeloid leukemia (AML). This application and the data on which it was based were filed by Bioenvision, Ltd. before the company was acquired by Genzyme last year.
GSK statement on MHRA investigation
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) notes the conclusions announced by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding its investigation into disclosure of paediatric trial data for the anti-depressant medicine Seroxat (paroxetine).
First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
- Details
- Category: Abbott
Data published in The Lancet from ABSORB, the world's first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (retreatment of a diseased lesion), and a low (3.3 percent) rate of major adverse cardiac events (MACE) in 30 patients out to one year.
Trial Date Set For SEROQUEL® Patent Litigation
- Details
- Category: AstraZeneca
AstraZeneca announced a trial date has been set for patent litigation in the US District Court for the District of New Jersey against Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of Abbreviated New Drug Applications (ANDAs).
Femara® helps protect against return of breast cancer
- Details
- Category: Novartis
Women may reduce the risk of their breast cancer returning by starting treatment with Femara® (letrozole) anywhere from one to seven years after finishing tamoxifen therapy, according to a new analysis published today in the Journal of Clinical Oncology[1].
Nycomed intends to move chemical production to Indian joint venture
- Details
- Category: Nycomed
Nycomed and Cadila Healthcare have signed a letter agreement with the intent to amend their existing joint venture agreement to include the chemical production of active pharmaceutical ingredients (APIs) by the joint venture company Zydus Nycomed in India. Based on this agreement, Nycomed plans to transfer the current chemical production from the sites in Linz (Austria) and Singen (Germany) to the new joint venture within the next three to four years.
More Pharma News ...
- Baxter and its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs
- A successful 2007 paves the way for future of Nycomed
- Amgen Announces Update to U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)
- Pfizer Wins Challenge to Two Main U.S. Patents for Celebrex
- DAIICHI SANKYO acquires osteoporosis medication EVISTA® from Lilly
- Genzyme Launches Renvela® in the U.S. for Dialysis Patients
- Pfizer Presents New Opportunities for Global Growth